Acetylcholinesterase inhibitors (AChEIs) represent an extensively investigated therapeutic approach for Alzheimer’s disease, based on the dual role of acetylcholinesterase (AChE) in both degrading acetylcholine and accelerating the formation of amyloid fibrils, which are critical pathological features of Alzheimer’s disease [151,152]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.